Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including ...